Pfizer has dosed the first patient in a trial of a muscular dystrophy gene therapy, acquired as part of its $700 million takeover of Bamboo in 2016.

The first trial of Translate Bio's nebulized messenger RNA therapy is now due to start in mid-2018, with results due a year later.

CymaBay's liver med seladelpar had "potent and sustained" efficacy in patients with primary biliary cholangitis.

The seroclearance gives a boost to Arrowhead as it plots a path back from safety concerns that derailed ARC-520 in 2016.

The FDA will make its decision on AbbVie's elagolix to Q3, as it needs more time to review liver function tests.

The Swedish biotech picked up small molecule multi-kinase inhibitor dovitinib in a belief its drug response predictor will up the chance of success.

Therapix Biosciences' THX-110 reduced Tourette symptoms in adults who had failed other treatments.

Antibiotics dubbed odilorhabdins (ODLs), inspired by soil-dwelling nematodes, hold promise for treating antibiotic-resistant infections.